Publications

Clinical pharmacokinetics

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

01-04-2018

Biomedical chromatography : BMC

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

01-04-2018

Therapeutic drug monitoring

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

01-04-2018

Journal of pharmaceutical and biomedical analysis

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

20-03-2018

Journal of neuro-oncology

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

01-03-2018

Pharmacological research

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

01-03-2018

Clinical pharmacokinetics

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

01-02-2018

Journal of pharmaceutical and biomedical analysis

Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride.

30-01-2018

Journal of pharmaceutical and biomedical analysis

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

30-01-2018

International journal of cancer

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

15-01-2018

Cancer chemotherapy and pharmacology

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

01-01-2018

Cancer chemotherapy and pharmacology

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

01-01-2018

Annals of oncology : official journal of the European Society for Medical Oncology

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

01-12-2017

Cancer chemotherapy and pharmacology

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

01-12-2017

Investigational new drugs

Human mass balance study and metabolite profiling of ¹⁴C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

01-12-2017

Thrombosis and haemostasis

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

01-12-2017

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

15-11-2017

Clinical pharmacology and therapeutics

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

01-11-2017

The Journal of antimicrobial chemotherapy

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

01-11-2017

European journal of cancer (Oxford, England : 1990)

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

01-11-2017

European journal of cancer (Oxford, England : 1990)

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

01-11-2017

Journal of pharmaceutical and biomedical analysis

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

25-10-2017

Molecular pharmaceutics

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

02-10-2017

Investigational new drugs

Pharmacokinetics and excretion of ¹⁴C-Plitidepsin in patients with advanced cancer.

01-10-2017

The pharmacogenomics journal

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

01-10-2017

The oncologist

Fixed Dosing of Monoclonal Antibodies in Oncology.

01-10-2017

Oncotarget

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

22-09-2017

BMC cancer

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

15-09-2017

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

01-09-2017

Clinical pharmacokinetics

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

01-09-2017

Pharmaceutical research

High-Tech Drugs in Creaky Formulations.

01-09-2017

International journal of pharmaceutics

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

30-08-2017

Investigational new drugs

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

01-08-2017

The oncologist

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

01-07-2017

Pharmacological research

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

01-06-2017

Therapeutic drug monitoring

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.

01-06-2017

British journal of cancer

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

23-05-2017

Drug development and industrial pharmacy

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

01-04-2017

Therapeutic drug monitoring

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

01-04-2017

FEBS open bio

The G2 checkpoint-a node-based molecular switch.

01-04-2017

Clinical pharmacokinetics

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

01-03-2017

Clinical cancer research : an official journal of the American Association for Cancer Research

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

01-03-2017

Journal of pharmaceutical and biomedical analysis

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

20-02-2017

Drug delivery and translational research

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

01-02-2017

Breast cancer research and treatment

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

01-02-2017

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

01-01-2017

Journal of clinical pharmacology

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

01-01-2017

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

20-12-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

01-12-2016

Therapeutic drug monitoring

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

01-12-2016

PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.

Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs.

Fast and Straightforward Method for the Quantification of Pazopanib in Human Plasma Using LC-MS/MS.

Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.

Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride.

Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients.

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.

Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization.

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

Enrichment of Circulating Endothelial Cells by CD34 Microbeads Followed by Enumeration Using Flow Cytometry.

An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma.

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir.

Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium.

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.

Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).

Pharmacokinetics and excretion of 14C-Plitidepsin in patients with advanced cancer.

Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.

Fixed Dosing of Monoclonal Antibodies in Oncology.

Intraductal cisplatin treatment in a BRCA-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction.

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.

High-Tech Drugs in Creaky Formulations.

Improving the solubility of nilotinib through novel spray-dried solid dispersions.

Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.

BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.

Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation.

Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.

Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.

Fast and Adequate Liquid Chromatography-Tandem Mass Spectrometric Determination of Z-endoxifen Serum Levels for Therapeutic Drug Monitoring.

The G2 checkpoint-a node-based molecular switch.

Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients.

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

Volumetric absorptive microsampling (VAMS) as an alternative to conventional dried blood spots in the quantification of miltefosine in dried blood samples.

Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.

This site uses cookies

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a ¹⁴C-microtracer and therapeutic dose in cancer patients.

Human mass balance study and metabolite profiling of ¹⁴C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer.

Pharmacokinetics and excretion of ¹⁴C-Plitidepsin in patients with advanced cancer.